- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 4
The Center for Biosimilars® recaps the top news for the week of February 4, 2019.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 4.
Number 5: Fresenius Kabi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for its biosimilar adalimumab.
Number 4: In a recent paper, Italian rheumatology providers called into question whether newly published results from the DANBIO registry can be used to guide non-medical switching.
Number 3: Researchers have provided detailed results from the phase 3 REFLECTIONS trial that found Pfizer's trastuzumab biosimilar to be equivalent to the EU reference.
Number 2: A recent white paper found that the assumption that Medicare Part B payment rates lead providers choose costlier treatments in order to benefit from larger add-on payments is incorrect.
Number 1: Mundipharma announced that it has launched Pelmeg, a biosimilar pegfilgrastim, in Germany, the Netherlands, and Ireland.
Finally, last week, our e-newsletter asked if drug makers should be required to disclose their research and development costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
